Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Mendel Tuchman, MD, Chief Research Officer at Children’s National, awarded NIH grant in Genetic Disease Outcomes Study

July 08, 2014

Washington, DC - Mendel Tuchman, MD, Chief Research Officer, Children’s Research Institute at Children’s National Health System, leads a team that was awarded a $650,000 grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to determine whether an amino acid-like-chemical can be used to improve the clinical outcome of genetic diseases characterized by elevated levels of ammonia in the blood, such as hyperammonemia.

Hyperammonemia is a metabolic condition that can cause severe brain damage, developmental disabilities, or be fatal. A chemical N-carbamylglutamate (NCG), similar to a small molecule in the liver, known as N-acetylglutamate (NAG), may be able to keep blood ammonia levels below toxic.

Tuchman and his team have found preliminary evidence that NCG can also reduce the blood ammonia levels in patients with a number of inherited metabolic diseases. Unlike NAG, NCG is not broken down in the body and can “mimic the effect of NAG to decrease ammonia levels in patients with a number of inherited metabolic diseases,” Tuchman wrote. The drug Carbaglu (carglumic acid) is used to treat chronic and acute hyperammonemia due to NAG deficiency and was approved by the Food and Drug Administration in March 2010.

The study project “will investigate whether Carbaglu can reduce ammonia levels in patients with four different genetic diseases associated with high ammonia levels,” Tuchman wrote.

 “If the results confirm our hypothesis,” Tuchman added, patients could be treated with Carbaglu “to keep their ammonia level at normal or close to normal levels, protecting them from brain damage.”

Prior to this study, Tuchman and colleagues have used Carbaglu for several patients with hyperammonemia, whose ammonia concentration declined rapidly after using the drug. The treatment of these patients reduced the need for frequent hospitalizations for hyperammonemia.

Dr. Tuchman holds the Mary Elizabeth McGehee Joyce Chair in Genetics Research at Children’s. He conducts translational research in biochemistry and molecular biology of nitrogen metabolism and inborn errors of metabolism. His work is supported by grants from the National Institutes of Health and he has published approximately 180 peer-reviewed articles.

Contact: Emily Hartman or Joe Cantlupe at 202-476-4500.

# # #

About Children's National Health System

Children’s National Health System, based in Washington, D.C., has served the nation’s children since 1870. Children’s National is one of the nation’s Top 5 pediatric hospitals and, for a second straight year, is ranked No. 1 in newborn care, as well as ranked in all specialties evaluated by U.S. News & World Report. It has been designated two times as a Magnet® hospital, a designation given to hospitals that demonstrate the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers in the D.C. Metropolitan area, including the Maryland suburbs and Northern Virginia. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is the seventh-highest NIH-funded pediatric institution in the nation. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. 

For more information, follow us on Facebook and Twitter.

Latest Tweets